doi: 10.1056/NEJMp1705800.
The Fate of FDA Postapproval Studies
Affiliations
- PMID: 28930510
- DOI: 10.1056/NEJMp1705800
Item in Clipboard
The Fate of FDA Postapproval Studies
N Engl J Med.
.
No abstract available
Comment in
-
FDA Oversight of Postmarketing Studies.N Engl J Med. 2017 Sep 21;377(12):1201-1202. doi: 10.1056/NEJMc1709185. N Engl J Med. 2017. PMID: 28930501 No abstract available.
-
The Fate of FDA Postapproval Studies.N Engl J Med. 2017 Dec 14;377(24):2404-5. doi: 10.1056/NEJMc1713794. N Engl J Med. 2017. PMID: 29240323 No abstract available.
Similar articles
-
Drug safety. Gaps in the safety net.Science. 2005 Jan 14;307(5707):196-8. doi: 10.1126/science.307.5707.196. Science. 2005. PMID: 15653480 No abstract available.
-
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410. JAMA Netw Open. 2019. PMID: 31074812 Free PMC article.
-
Accelerated approval of oncology products: the food and drug administration experience.J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422403 Review.
-
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.BMJ. 2017 May 3;357:j1680. doi: 10.1136/bmj.j1680. BMJ. 2017. PMID: 28468750 Free PMC article. Review.
-
The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?Food Drug Law J. 2006;61(2):295-383. Food Drug Law J. 2006. PMID: 16903034 No abstract available.
Cited by
-
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.JAMA Health Forum. 2022 May 27;3(5):e221158. doi: 10.1001/jamahealthforum.2022.1158. eCollection 2022 May. JAMA Health Forum. 2022. PMID: 35977252 Free PMC article.
-
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.JAMA Netw Open. 2022 Aug 1;5(8):e2225973. doi: 10.1001/jamanetworkopen.2022.25973. JAMA Netw Open. 2022. PMID: 35947385 Free PMC article.
-
A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.Front Med (Lausanne). 2022 Jun 14;9:893400. doi: 10.3389/fmed.2022.893400. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35775007 Free PMC article.
-
Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014.Clin Pharmacol Ther. 2022 Oct;112(4):846-852. doi: 10.1002/cpt.2679. Epub 2022 Jun 23. Clin Pharmacol Ther. 2022. PMID: 35662000 Free PMC article.
-
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.Drug Saf. 2022 Apr;45(4):305-318. doi: 10.1007/s40264-022-01152-9. Epub 2022 Feb 19. Drug Saf. 2022. PMID: 35182362
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
